By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences and Target Discovery today announced they have expanded a technology license and supply agreement.

Under the expansion, Target Discovery will be able to use Pressure Bio's Pressure Cycling Technology platform for a planned entry into the clinical diagnostics testing space, they said, adding that the planned diagnostic services target critical unmet needs in treatment selection guidance for ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.